Recent News

• 12.15.2025 - Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
• 12.08.2025 - Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
• 12.03.2025 - Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
• 10.09.2025 - Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
• 10.02.2025 - Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
• 09.30.2025 - Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
• 09.18.2025 - Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
• 09.10.2025 - Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
• 08.20.2025 - Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
• 08.19.2025 - Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Recent Filings

• 11.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - ARS Annual Report to Security Holders
• 11.03.2025 - DEF 14A Other definitive proxy statements
• 11.03.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]